drugset / Trial / NCT05056116
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Phase Ⅱ, open-label, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-06
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 250 mg | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |